Skip to Main Content

Paper Details

A PD-L1/EGFR bispecific antibody combines immune checkpoint blockade and direct anti-cancer action for an enhanced anti-tumor response.
Oncoimmunology
6
2023
Author NameAffiliation
Jaume BonetInstitute of Bioengineering, Ecole Polytechnique Federale de Lausanne
  • 1 - 1

Datasets

Release 1.2